Daiichi Sankyo Options Amplimmune’s Second Clinical Program
This article was originally published in The Pink Sheet Daily
Founded in 2007, Amplimmune out-licensed its first immune-modulation program, for cancer, to GlaxoSmithKline in 2010. Now, the Maryland biotech has signed an option under which the Japanese pharma can license its second clinical candidate, for an undisclosed autoimmune indication, up to the end of Phase IIa.
You may also be interested in...
Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.